How to Get Published in Nature: What Editors Actually Look For

Nature's own description of its scope is useful: it publishes research of exceptional importance that advances scientific knowledge and has broad appeal. The key phrase is "broad appeal." A paper that makes a fundamental contribution to structural biology but is only of interest to structural biologists won't make it at Nature - it belongs in a specialty journal. A paper that reveals a universal principle about how cells respond to stress, written in a way that immunologists, neuroscientists, and cancer biologists can all learn from, is exactly what Nature wants.The findings that succeed at Nature tend to share a few characteristics. They establish something genuinely new - not a refinement of an existing model but a challenge to it, an extension into new territory, or a discovery of something previously unknown. They use methods that are state-of-the-art for the question being asked. And they're written to be understood by scientists across disciplines, not just specialists in the subfield.What doesn't make it: technically excellent incremental work, confirmatory studies that strengthen existing models without overturning them, findings of primary interest to a single specialist community, and work where the main advance is methodological rather than conceptual.

Nature editors reject approximately 60% of manuscripts at the desk, a figure the journal's editors have stated publicly. Nature receives over 20,000 submissions per year and publishes under 7% of them. That means the majority of authors who submit to Nature never receive reviewer feedback - they receive an editorial rejection within one to two weeks.Desk rejections happen when a handling editor determines that a manuscript doesn't meet Nature's threshold for broad significance or genuine novelty. Editors are generalist scientists with broad scientific reading. They're asking: is this finding new, does it matter beyond this subfield, and would a Nature reader who isn't a specialist in this area care about this result?The most common desk rejection scenarios:- A finding that's novel within a subfield but doesn't represent a conceptual advance that reaches beyond it- A mechanism established in a model system without evidence that it applies broadly- A claim of first-in-field that doesn't hold up against the recent literature- Incremental contributions to an established body of work, regardless of sample size or technical sophisticationAvoiding desk rejection starts with being honest about whether your finding genuinely meets the broad-significance bar. If it requires significant specialist knowledge to understand why it matters, it probably doesn't.

Novelty at Nature doesn't mean "this hasn't been shown before." It means "this changes how we think about something fundamental." There's a meaningful difference between those two things.A paper that identifies a new gene involved in a known pathway is novel in the narrow sense - the gene wasn't previously identified. But it doesn't change the conceptual framework for understanding the pathway. A paper that shows a mechanism everyone assumed was cell-autonomous is actually systemic - that changes how the whole field thinks about the problem. That's Nature-level novelty.Before submitting to Nature, ask: if this paper were published tomorrow, would researchers in three other fields care about it? Would it change how a neuroscientist, a cancer biologist, and a microbiologist think about their work? If the honest answer is only one of those three, it's probably a specialty journal paper regardless of technical quality.

Nature reviewers pay close attention to figures. The standard expectation is that the main figures tell a complete, compelling story in sequence - from the observation that motivated the study, through the mechanism, to the functional significance, with each panel building logically on the last.A few specific things that come up in Nature reviews:Model system validation is increasingly expected. Findings in a single model system - one cell line, one mouse strain, one organism - face questions about generalizability. Papers that validate a mechanism across two or three systems, or that include human tissue validation alongside animal model data, are substantially stronger.Quantitative rigor is assumed. Statistical approaches need to be appropriate for the experimental design. N values need to be stated clearly. Error bars need to be defined. Multiple independent experiments or biological replicates are expected, not pooled technical replicates.The final figure should close the loop. It should show the functional relevance of the mechanism established in earlier figures. A paper that identifies a mechanism without demonstrating that the mechanism matters functionally - that its disruption has a measurable consequence - leaves a gap that reviewers will flag.

At Nature, the cover letter is read. It's typically the first thing the handling editor sees before opening the manuscript. A cover letter that's a one-paragraph abstract summary wastes the opportunity.An effective Nature cover letter does three things:First, it establishes the fundamental problem and why it's unresolved. Not the entire field's history - two sentences that frame the gap. Second, it describes the central finding and makes the case for why it's a major advance, not an incremental one. This is where you argue broad significance. "Our finding that X challenges the longstanding assumption that Y" is the kind of statement that catches attention. Third, it explains the cross-disciplinary appeal. Why does this matter to scientists beyond your immediate specialty?Keep it to three paragraphs. Editors read dozens of cover letters a day. A concise letter that makes the significance clear in 300 words is more effective than a thorough one that takes 600 words to get there.

Most groups don't lose time because the science is weak. They lose time because the submission sequence is sloppy. A manuscript goes out with one unresolved weakness, gets predictable reviewer pushback, then the team spends 8 to 16 weeks fixing something that could have been caught before first submission. That's why a good pre-submission pass pays for itself even when the paper is already strong. You aren't buying generic feedback. You're buying a faster path to a decision that can actually move your project forward.

Use a three-pass process. Pass one is claim integrity. For each major claim, ask what figure carries it and what competing explanation still survives. Pass two is reviewer simulation. Force one person on your team to argue from a skeptical reviewer position and write five hard comments before submission. Pass three is journal-fit edit. Tighten title, abstract, and first two introduction paragraphs so the paper reads like it belongs to that exact journal, not just any journal in the field. Teams that do this often reduce first-round revision scope by one-third to one-half.

A lot of rejections come from mismatch, not low quality. The data may be strong, but the manuscript promises more than it suggests. Or the discussion claims broad relevance while the experiments only establish a narrow result. Another common issue is sequence logic. Figure 4 may be decisive, but it's buried after two weaker figures, so reviewers form a negative opinion before they reach the strongest evidence. Reordering figures and tightening claim language sounds minor, but it changes reviewer confidence quickly.

Here's a realistic timeline from teams we see often. Week 0: internal final draft. Week 1: external pre-submission review with field specialist comments. Week 2: targeted edits to claims, methods clarity, and figure order. Week 3: submit. Week 4 to 6: editor decision or external review invitation. Week 8 to 12: first decision. Compare that with the no-review path, where first submission leads to avoidable rejection and the same manuscript isn't resubmitted for another 10 to 14 weeks. The science hasn't changed, but total cycle time has.

Nature explicitly accepts pre-submission enquiries. This is an underused tool that can save you months. A pre-submission enquiry requires:

1. A cover paragraph stating why the work has broad scientific interest (not just field-level importance)
2. A fully referenced summary paragraph describing the finding and its significance
3. A reference list

Send this to the appropriate editor. The response typically comes within 1-2 weeks and tells you whether the work is within scope and broad enough to justify full submission. A "not suitable" response saves you from formatting the full manuscript, writing the cover letter, and waiting for a desk rejection. A positive response doesn't guarantee acceptance but means an editor has already signaled interest.

This costs nothing and takes an afternoon to prepare. For papers where Nature fit is genuinely uncertain, it's the highest-ROI action you can take.

Not every manuscript needs the same depth of feedback. If your team has two senior PIs with recent publications in the same journal tier, a focused external review may be enough. If this is a first senior-author paper, or the target journal is above your group's recent publication history, you need deeper critique on novelty framing and expected reviewer asks. Also decide whether speed or certainty matters more. A 48-hour light pass can catch clarity issues. A 5 to 7 day field-expert review is better for scientific risk.

• authors deciding whether a manuscript is genuinely broad enough for Nature rather than a specialist flagship
• teams that need to pressure-test novelty, figure order, and cross-disciplinary significance before first submission
• labs building a realistic submission ladder from Nature to strong field journals without wasting a cycle on avoidable mismatch